N-Boc-L-Prolinal

[1]. Wang X, et al. Synthesis and biological activity evaluation of dolastatin 10 analogues with N-terminal modifications. Tetrahedron. 2017 Apr 20;73(16):2255-66. [Content Brief]

[2]. Bocci M, et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. Journal of controlled release : official journal of the Controlled Release Society. 2024 Mar;367:779-790. [Content Brief]

[3]. Jackson JJ, et al. Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T Trafficking into the Tumor Microenvironment. Journal of medicinal chemistry. 2019 Jul 11;62(13):6190-6213. [Content Brief]

[4]. Chiba J, et al. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist. Bioorganic & medicinal chemistry letters. 2005 Jan 03;15(1):41-5. [Content Brief]

[5]. Wallén EA, et al. 4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorganic & medicinal chemistry. 2002 Jul;10(7):2199-206.

[6]. Podichetty AK, et al. Fluorinated isatin derivatives. Part 3. New side-chain fluoro-functionalized pyrrolidinyl sulfonyl isatins as potent caspase-3 and -7 inhibitors. Future medicinal chemistry. 2009 Aug;1(5):969-89.

[7]. Gutman H, et al. Discovery of Dolastatinol: A Synthetic Analog of Dolastatin 10 and Low Nanomolar Inhibitor of Tubulin Polymerization. ACS medicinal chemistry letters. 2021 Oct 14;12(10):1596-1604. [Content Brief]